Concepedia

Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer

Jingwan Zhang, Ying Lin, Xiaonan Sun, Bi Yan Wang, Z.H. Wang, Jianfeng Luo, S Zhang, Ji Cao, Zhonghua Tao, Jiong Wu,

Annals of Oncology · 2018 · 74 citations · 15 references

DOIFull text

Open access

Concepts

References

15

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Roy S. Herbst, Jean‐Charles Soria, Marcin Kowanetz et al. · Nature · 2014 · 5.3K citations

, , +16

Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98

Sherene Loi, Nicolas Sirtaine, Fanny Piette et al. · Journal of Clinical Oncology · 2013 · 1.6K citations

, , +17

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

Sherene Loi, Stefan Michiels, Roberto Salgado et al. · Annals of Oncology · 2014 · 1.3K citations

, , +15

Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers

Carsten Denkert, Gϋnter von Minckwitz, Jan C. Brase et al. · Journal of Clinical Oncology · 2014 · 1K citations · Full text

, , +17

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial

Andrew Tutt, Holly Tovey, Maggie C.U. Cheang et al. · Nature Medicine · 2018 · 903 citations · Full text

, , +11